Novartis Ag

Joy Gispati Ghosh

Michael Roguska

Igor Splawski

Michael Stefanidakis

Barbara Brannetti

Kathrin Ulrike Tissot-Daguette

Ute Jaeger

Yong-In Kim

Christian Carsten Silvester Kunz

Sha-Mei Liao

Leslie Ngozi Anuna Johnson

Mark Anthony Rutz

Thaddeus Peter Dryja

Bijan Etemad-Gilbertson

Nicole Haubst

Chad Eric Bigelow

Yunsheng He

Engin Toksoz

Stephen Hedrick Poor

Nina Moker

Eric C Carlson

Ana Maria Carrion

James Edgar Chastain

Kirk Lee Clark

Shawn Michael Hanks

Ganesh Rajan Iyer

Andrew Anh Nguyen

Yubin Qiu

Nalini Velamur Rangaswamy

Michael Zbigniew Twarog

Leslie Johnson

Katrin Ulrike Tissot-Daguette

The invention features methods of identifying patients as being likely to respond to anti-VEGF therapy. Furthermore, in those patients identified as failing to include one or more of the above ophthalmic response markers, the invention features treatment with an EPO antagonist (e.g., alone, or in combination with a VEGF antagonist).

Methods of treating ophthalmic disorders

The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.

Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules

The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).

Nucleic acids encoding anti-Factor P antibodies

The invention provides compositions for rendering a vitreous cavity visible during a surgical procedure to alleviate a structural disorder caused by the vitreous in an eye, and methods of using the compositions. The compositions are vitreous delineating agents that comprise a hyaluronan binding peptide linked to an optically detectable moiety. Such compositions can be in a formulation that may be a solution, a suspension, or an emulsion, and would be injected into the vitreous shortly prior to use. The composition may additionally contain a therapeutic agent, a diagnostic agent, or a chemosensing material, in use, the composition marks or delineates the vitreous by binding preferentially to the hyaluronan that permeates the vitreous humor and binding little or not at all to surrounding tissues such as the retina. The interface between the labelled vitreous humor and the non-labelled surrounding vital tissues produces a visible signal, thereby allowing a surgeon to clearly visualize the entire vitreous cavity and distinguish it from vital ocular structures. Use of the method improves the accuracy and safety of a vitrectomy and thus prevents suboptimal outcomes or the need for repeated procedures. The compositions comprising chemosensing material are useful as long-lasting biosensors, which when used in the vitreous enable repetitive, non-invasive, in vivo measurements of metabolites or pharmacologic agents in the vitreous of animals or humans.

Compositions and methods for visualization of the vitreous

The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.

Compositions and methods for antibodies targeting EPO

Compositions and methods for antibodies targeting Epo

Compositions comprising antibodies targeting factor P

Antibodies that bind factor P

Growing community of inventors

Boston, MA, United States of America

Joy Gispati Ghosh